Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732 by 源��쑀誘� et al.
455Assessment of the anti-obesity effects of the TNP-470 analog,
CKD-732Yoo Mee Kim, Juan Ji An1,2, Yong-Jun Jin4, Yumie Rhee1,2,3, Bong Soo Cha1,2,3,
Hyun Chul Lee1,2,3 and Sung-Kil Lim1,2,3
Division of Endocrinology, Department of Internal Medicine, NHIC Ilsan Hospital, Goyang, Republic of Korea
1Division of Endocrinology, Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea
2BK21 Project for Medical Science, College of Medicine, Yonsei University, Seoul, South Korea
3College of Medicine, Institute of Endocrine Research, Yonsei University, Seoul, South Korea
4Division of Endocrinology, Department of Internal Medicine, YanBian University, Medical College, Affiliated Hospital, YanJi, People’s Republic of China
(Requests for offprints should be addressed to S-K Lim who is now at Division of Endocrinology, Department of Internal Medicine, College of Medicine,
Yonsei University, 134 Shinchon-dong Seodaemun-ku, PO Box 120-749, Seoul, South Korea; Email: lsk@yumc.yonsei.ac.kr)AbstractThe systemic treatment with angiogenesis inhibitor has been shown to result in weight reduction and adipose tissue loss
in various models of obesity. To verify the mechanism of CKD-732 (TNP-470 analog) against obesity, we evaluated
CKD-732’s peripheral and central anti-obesity effects. CKD-732 was injected subcutaneously (s.c.) for 7 days in various
animal models and intracerebroventricularly (i.c.v.) in arcuate nucleus (ARC) lesion mice, ob/ob mice, and normal
littermates. Modulation of the hypothalamic neuropeptide mRNAs after i.c.v. injection was evaluated in ARC lesion mice
and normal littermates. A conditioned taste aversion (CTA) was performed using lithium chloride (LiCl) as a positive
control agent in Long–Evans Tokushima Otsuka and Otsuka Long–Evans Tokushima fatty (OLETF) rats. As a result,
7 days of CKD-732 s.c. injection reduced the cumulative food intake and the body weight significantly in both treated
obese (e.g. 114.8G13.4 g vs 170.7G20.6 g, 7.9G0.5% decrease vs 0.3G2.2% decrease; in treated OLETF rat versus
control OLETF rat, P!0.01 respectively) and non-obese models. Epididymal and mesenteric fat pads, and the size of
adipocytes were significantly decreased in treated rats. A single i.c.v. injection decreased food intake and body weight in
ARC lesion mice and ob/ob mice but not in normal littermates. Unexpectedly, the hypothalamic neuropeptide mRNAs
were not altered by single i.c.v. injection. CKD-732 also induced a dose-dependent CTA comparable with LiCl injection,
which is a commonly used agent to produce a CTA. In conclusion, CKD-732 causes significant body weight and appetite
reduction, possibly by decreasing adiposity directly and inducing central anorexia, which is partly explained by a CTA.
These results should be carefully verified to assess the utility of CKD-732 as an anti-obesity drug.Journal of Molecular Endocrinology (2007) 38, 455–465Introduction
Obesity is highly prevalent in many developed countries
and its prevalence is increasing worldwide (Kopelman
2000). Diet and exercise remain the cornerstones of
obesity management; however, it is likely that many
patients will require an anti-obesity drug to reduce body
weight and prevent complications (Bray & Tartaglia
2000). As drugs used in the past to treat obesity have
caused unacceptable mortality and morbidity, there is a
need for more effective and better tolerated anti-obesity
drugs (Weigle 2003). Impaired fuel metabolism is an
early pathogenic factor in obesity and type 2 diabetes
mellitus (Minokoshi et al. 2002). Frequently, daily
energy intake is variable within and among individuals,
and is not well correlated with daily energy expendi-
ture. Despite short-term mismatches in energy balance,
however, most people match cumulative energy intakeJournal of Molecular Endocrinology (2007) 38, 455–465
0952–5041/07/038–455 q 2007 Society for Endocrinology Printed in Great Britainand expenditure with great precision over a period that
spans many meals. This phenomenon reflects an active
regulatory process, termed energy homeostasis, which
promotes stability in the amount of body energy stored
in the form of fat (Schwartz et al. 2000). Among these
regulatory processes, the central regulation of fuel
homeostasis has been highlighted.
In searching for new anti-obesity drugs, Rupnick et al.
(2002) have recently speculated that neovascularization
may be critical for adipose tissue growth. They showed
that systemic treatment with angiogenesis inhibitors
resulted in weight reduction and adipose tissue loss in
various mouse models of obesity (Rupnick et al. 2002).
This concept was developed due to the unique feature
of the microvasculature within adipose tissue. Since
adipose tissue has enormous growth potential given the
appropriate metabolic challenge, it displays a high
degree of plasticity with respect to its vascularization.DOI: 10.1677/jme.1.02165
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blood vessels from existing ones, often precedes
adipogenesis in developing adipose tissue micro-
vasculature (Crandall et al. 1997).
The concept linking new blood vessel formation
with tumor growth and metastases was proposed more
than 20 years ago. Since Ingber et al. (1990) discovered
that fumagillin from Aspergillus fumigatus inhibits new
blood vessel growth, many semi-synthetic fumagillin
analogs have been synthesized from fumagillol, the
hydrolysis product of fumagillin. Of these angiostatic
compounds, fumagillin and its derivative, TNP-470,
inhibit neovascularization via endothelial cell cycle
arrest in the late G1 phase (Abe et al. 1994). Methionine
aminopeptidase-2 (MetAP2) has been identified as a
molecular target. However, the link between MetAP2
inhibition and endothelial cell cycle arrest by fuma-
gillin and TNP-470 remains unclear (Griffith et al. 1997,
Sin et al. 1997). We used a synthetic derivative of TNP-
470, which has been proven to have higher affinity to
MetAP2 and higher efficacy on suppression of in vivo
tumor growth compared with TNP-470 (Chun et al.
2005). Previous reports have suggested that TNP-470
reduces body weight and slightly decreases food intake
in various animal models of obesity (Rupnick et al.
2002). However, the precise mechanism of action
remains unknown, and the long-term safety of the
drug aimed at anti-obesity treatment has not been
clearly proven.
Among various endeavors to develop new drugs for
obesity, many data indicate that pharmacotherapies
based on the melanocortin (MC) system might provide
useful tools in the treatment of obesity. This neuro-
peptide system is now thought to be critical for the
regulation of food intake and energy balance (Fan et al.
1997, Schwartz et al. 1997, Thornton et al. 1997, Mizuno
et al. 1998, Thiele et al. 1998). Disruption of MC
signaling leads to obesity and MC neurons appear to
mediate the anorexic effects of the adipocyte hormone,
leptin (Huszar et al. 1997, Seely et al. 1997). However, at
least one potential difficulty in utilizing MC agonists as
anorexic agents in humans is that the mixed MC
agonist melanotan-II (MTII) reportedly produces a
mild conditioned taste aversion (CTA) (Benoit et al.
2003). The CTA is thought to be caused by agents that
produce adverse effects, like those of visceral illness.
In other words, if rats are made ill after consumption of
a novel flavor, then they avoid that flavor when
encountered again, which is a phenomenon called a
CTA. According to Benoit et al. (2003), the reduction in
food intake caused by MTII is accompanied by CTA
regardless of administration route.
In this study, we evaluated CKD-732’s peripheral and
central anti-obesity effects. To verify the mechanism of
action of CKD-732 against obesity, we investigated the
peripheral and central effects on body weight, foodJournal of Molecular Endocrinology (2007) 38, 455–465intake, and core temperature by subcutaneous (s.c.) or
intracerebroventricular (i.c.v.) injection. The modu-
lation of hypothalamic neuropeptide mRNAs after
i.c.v. injection and the development of a CTA by s.c.
injection were also evaluated to authenticate the
mechanism for anorexia induced by CKD-732.Materials and methods
Animals
Male obese animals such as arcuate nucleus (ARC)
lesion mice, 7-week-old C57BL/6J ob/ob mice (Central
Lab. Animal Inc., Seoul, South Korea), and 6-week-old
Otsuka Long–Evans Tokushima fatty (OLETF) rats
(Tokushima Research Institute Otsuka Pharmaceutical
Co. Ltd, Tokushima, Japan) were obtained. Six-week-
old C57BL/6J mice from the Jackson Laboratory
(Daehan Biolink Co. Ltd, Seoul, South Korea),
Sprague–Dawley (SD) rats (Daehan Biolink Co. Ltd),
and Long–Evans Tokushima Otsuka (LETO) rats
(Tokushima Research Institute Otsuka Pharmaceutical
Co.) were also obtained and used as controls. These
animals were maintained using a ratio of 12 h light:12 h
darkness cycle at 23 8C under the institutional guide-
lines for the humane treatment of laboratory animals.
Mice and rats were housed with free access to food and
water. PicoLab Rodent Diet 20 5053 (PMI Nutrition
International, St Louis, MO, USA) was provided as their
general rodent diet. After a 1-week acclimation,
C57BL/6J mice and developed ARC lesion mice were
administered s.c. injection for 7 days or single i.c.v.
injection of CKD-732. The CKD-732 was also i.c.v.
injected in C57BL/6J ob/ob mice after 1-week acclim-
ation. The SD rats and 18-week-old LETO and OLETF
rats were administered s.c. injection of CKD-732 daily.
All experimental protocols were approved by the
Animal Ethics Committee at the Yonsei University
College of Medicine (Seoul, South Korea).Drugs
Monosodium glutamate (MSG), lithium chloride
(LiCl), and saccharin were purchased from Sigma.
A synthetic TNP-470 analog, CKD-732 (6-O-(4-dimethyl-
aminoethoxy) cinnamoyl fumagillol hemioxalate) was
kindly provided by Chong Kun Dang Pharmaceutical,
Seoul, South Korea. CKD-732 is known to be 1000 times
more active than TNP-470 in vitro. Moreover, CKD-732
has been proven to be more effective in inhibition of
human umbilical vein endothelial cells (HUVEC)
growth and induction of cell cycle arrest in HUVEC
when compared with TNP-470. The CKD-732 also
significantly suppressed in vivo tumor growth, and its
efficacy was much higher than TNP-470 (12). CKD-732www.endocrinology-journals.org
Anti-obesity effects of CKD-732 . Y M KIM and others 457was dissolved in 0.9% NaCl and s.c. injected with doses
of 0.1, 1, 5, or 10 mg/kg of body weight and i.c.v.
injected with a single dose of 0.5, 1, 1.5, 2, 3, or
5 mg/2 ml artificial cerebrospinal final (aCSF) using the
stereotaxic technique.Development of ARC lesion mice
For the development of ARC lesions, pregnantC57BL/6J
mice were housed alone before delivery. Fromdays 1 to 7,
offspring were s.c. injected daily with either MSG
(2 mg/g body weight) or 0.9% NaCl (Spurlock et al.
1996). Animals were weaned at 21 days of age and then
housed in groups of the same sex. All animals were
allowed free access to water and standard rodent chow.
Control and MSG-treated (ARC lesion) male mice were
studied at 12 weeks of age. After death, their brains were
removed and frozen with liquid nitrogen. The brains
were later sectioned through the hypothalamus on a
cryostat and the brain sections were fixed with
paraformaldehyde. The sections were stained with Cresyl
violet and then examinedunder amicroscope to confirm
the presence or absence of ARC lesions.Measurement of food intake, body weight, and core
temperature
Daily food intakewasmeasured during 7 days of CKD-732
s.c. injection, and 4 h and 24 h after i.c.v. injection. Daily
body weight was measured during 7 days of s.c. injection
and until 2 weeks after CKD-732 withdrawal. Body weight
change was also measured 24 h after i.c.v. injection. Core
temperature was measured in fasted animals using a
digital thermometer (Toshiba, Tokyo, Japan).Measurement of liver weights and regional fat
contents
LETO and OLETF rats were anesthetized with
ketamine (100 mg/kg; Korea United Pharm., Seoul,
South Korea) and xylazine (10 mg/kg; Bayer Korea
Ltd). Rats were killed after aortic puncture and the liver
and the epididymal, mesenteric, and perirenal fat pads
were dissected, weighed, and frozen in liquid nitrogen.Measurement of the absolute number and size of
adipocytes by histopathology
The epididymal fat pads were fixed in 10% formalin
neutral buffer (pH 7.4) and demineralized in nitric
acid. Cut sections along with a perpendicular line of
intercondylar fossa were embedded in paraffin.
Sections 4 mm thick were cut using a microtome,
stained with hematoxylin and eosin, and examined
under a light microscope with an image analyzerwww.endocrinology-journals.org(Image Pro, Silver Spring, MD, USA). Three cut
sections of the same specimen were examined and the
adipocytes were counted in each high power field
(HPF) to calculate the absolute number and the size of
adipocytes in each field.Reverse transcription-PCR (RT-PCR)
To obtain the hypothalamus, the C57BL/6J and ARC
lesionmicewerekilled1 hafter i.c.v. injectionofCKD-732
at a dose of 3 mg/2 ml aCSF. The hypothalami were
dissected from decapitated animals and immediately
frozen. Total RNA was extracted from the dissected
hypothalamus with a commercial RNeasy kit (Qiagen)
according to the manufacturer’s instructions. The purity
and the amount of isolated RNA were assessed by
spectrophotometric measurement at 260 and 280 nm.
Total RNA (5 mg) was reverse transcribed to cDNA at
42 8C for 50 min in a solution with a total volume of 20 ml
containing the following reagents: 0.5 mM dNTP mix-
ture, 10 mM dithiothreitol, 0.5 mg Oligo (dT), buffer
(250 mM Tris, 375 mM KCl, and 15 mMMgCl2, pH 8.3),
and 5 U AMV (RNase H-free reverse transcriptase), all of
which were obtained from Promega. The reaction was
terminated at 70 8C for 15 min. The cDNA aliquots were
diluted in the ratio from1:1 to 1:100. RT-PCR analysis was
performed as previously described, under the following
conditions 94 8C, 5 min; 94 8C, 30 s; 52 8C, 30 s; 72 8C,
1 min (repeated for 30 cycles); and 72 8C, 15 min. The
following oligonucleotides were used for RT-PCR amplifi-
cation: neuropeptide Y, (NPY); forward, 50-CTAGGTAA-
CAAGCGAATGGGG-30; reverse, 5 0-ACATGGAAGGGT
CTTCAAGCC-30; agouti-relatedprotein(AgRP), forward,
50-TGCTGAGTTGTGTTCTGCTGT-30; reverse, 5 0-AGT
GGACTCAGGTCAGGGA-3 0; pro-opiomelanocortin,
(POMC); forward, 5 0-AACAGCAGCAGTGCTGGCA-3 0;
reverse, 5 0-AAGTGCTCCACCCGGTAGG-3 0; melanin
concentrating hormone, (MCH); forward, 5 0-GCAAAG
ATGACTCTCTCTTCC-3 0; reverse, 5 0-GACTTGCCAA-
CATGGTCGGTA-3 0; b-actin, forward, 5 0-TTCAA-
CACCCCAGCCATGT-3 0; reverse, 5 0-TGTGGTACG
ACCAGAGGCATAC-3 0.Analysis of a CTA
LiCl is commonly used as a toxic agent to produce a CTA.
Inorder to testCTA, amodifiedmethod fromBenoit et al.
(2003) was used. OLETF and LETO rats were first
habituated to 1 h access to water. For 7 days, tap water
was replacedwithwater containing0.1%saccharin.Then,
the ratswere given1 h access to tapwater for 2days. These
rats received a single s.c. injection of either saline, LiCl
(0.15 M at 2% body weight), or two different doses of
CKD-732 (1 or 10 mg/kg in a volume of 2 ml/kg) just
after 1 h exposure to the saccharin solution. On theJournal of Molecular Endocrinology (2007) 38, 455–465
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bottles of tap water. On the subsequent day, a two-bottle
choice test was administered in which all rats were given
1 haccess to tapwater and the saccharin solution,with the
relative position of the two solutions counterbalanced
across subjects. The preference ratio (saccharin solution
intake divided by total fluid intake) was calculated from
the results of the final experimental day.
Statistical analysis
All parameters were analyzed by SAS V8.1 (Cary, NC,
USA). All values were reported as meansGS.D. Statistical
significance was determined by using the Student’s t-test
and one-way ANOVA followed by Tukey’s post hoc test. A
value of P!0.05 was taken to indicate statistical
significance.Results
Effect of CKD-732 on food intake, body weight, and
core temperature
To investigate the in vivo effect of CKD-732 on food
intake and body weight, CKD-732 was s.c. injected forFigure 1 Cumulative food intake by CKD-732 s.c. injection; nZ20 per
(C) SD rat, and (D) LETO/OLETF rat. *P!0.05; †P!0.01 vs control b
Tukey’s post hoc analysis.
Journal of Molecular Endocrinology (2007) 38, 455–4657 days at different doses: C57BL/6J mice, 5 mg/kg per
day; ARC lesion mice, 1 mg/kg per day; SD rats,
5 mg/kg per day; LETO rats, 1 mg/kg per day; and
OLETF rats, 1 mg/kg per day. Seven days of CKD-732
s.c. injection decreased cumulative food intake in all
animals, but to a greater extent in obese models
including the ARC lesion mice and OLETF rats (e.g.
114.8G13.4 g for treated OLETF rat versus 170.7G
20.6 g for control OLETF rat, P!0.01 by Student’s t-
test, Fig. 1). Accordingly, these animals demonstrated a
significant decrement in body weight; up to a 44G3 g
decrease was shown in OLETF rats with only 7 days of
CKD-732 injection, and whose basal mean body weight
was 567.8G16.6 g (Fig. 2). In other words, a 7.9G0.5%
body weight decrease was obtained in treated OLETF
rats when compared with a 0.3G2.2% decrease in
control OLETF rats within 7 days of treatment (P!0.01
by Student’s t-test).
To investigate CKD-732’s effect on energy expendi-
ture, we measured the core temperature of fasted ARC
lesion mice after 7 days of CKD-732 treatment. The core
temperature of CKD-732-treated ARC lesion mice was
greater than saline-treated ARC lesion mice, which
suggests an increase of energy expenditure upon CKD-
732 treatment (Fig. 3A).each animal model. (A) C57BL/6J mouse, (B) ARC lesion mouse,
y Student’s t-test. ‡P!0.05 by one-way ANOVA followed by
www.endocrinology-journals.org
Figure 2 Body weight (BW) change by CKD-732 s.c. injection; nZ20 each per animal model. (A) C57BL/6J mouse, (B) ARC lesion
mouse, (C) SD rat, and (D) LETO/OLETF rat. *P!0.05; †P!0.01 vs control by Student’s t-test. ‡P!0.05 by one-way ANOVA followed by
Tukey’s post hoc analysis.
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weight after CKD-732 withdrawal in ARC lesion mice.
We found that if CKD-732 treatment was discontinued
after 7 days of s.c. injection, body weight slowly returned
to the basal level within 2 weeks (Fig. 3B). This result
suggests the idea of using repetitive on and off
treatment to minimize weight cycling and maximize
long-term weight maintenance.
When CKD-732 was s.c. injected at a higher dosage
(10 mg/kg) for 7 days, LETO and OLETF rats
experienced anorexia from the first day of treatment
and their body weight significantly decreased from the
second day of treatment (Fig. 3C and D). This rapid
induction of anorexia was similarly observed in both
LETO and OLETF rats.Effect of CKD-732 on liver weights, regional fat
contents, and size of adipocytes
To investigate CKD-732’s effect on liver weights, regional
fat contents, and size of adipocytes, LETO and OLETF
ratswerekilledafter 7daysofCKD-732 treatment.Weights
of the liver were not significantly different between CKD-
732-treated and control LETO rats (14.0G0.3 g/rat vswww.endocrinology-journals.org14.4G0.2 g/rat, PZ0.134), and CKD-732-treated and
control OLETF rats (19.2G0.3 g/rat vs 19.7G0.3 g/rat,
PZ0.065). In CKD-732-treated LETO and OLETF rats,
regional fat pad weights, especially epididymal and
mesenteric fat pads, were significantly decreased
(Fig. 4). Moreover, by histopathologic examination, the
number (n) and size (m2) of adipocytes per HPF were
calculated. As shown in Fig. 5, the size of adipocytes
decreased significantly in CKD-732-treated LETO and
OLETF rats. However, the change in endothelial cells
could not be evaluated in these cut sections due to stain
methoddifferences. In addition, we foundno evidence of
adipose tissue necrosis by microscopic evaluation. From
these results, although the precise mechanism is still
unknown, we suggest that the antiangiogenic signal
inducedbyCKD-732directly influences the adipose tissue
to shrink significantly, and as a consequence, adipocyte
size decreases.Mechanism of action of CKD-732 on reducing body
weight and food intake
To determine how CKD-732 reduces body weight and
food intake, we evaluated the central anorexic effect ofJournal of Molecular Endocrinology (2007) 38, 455–465
Figure 3 Effect on core temperature and change of body weight (BW) after CKD-732 treatment withdrawal, and high-dosage effects.
(A) The core temperature of ARC lesion mice was significantly increased after 7 days of CKD-732 s.c. injection; nZ10 per each subgroup.
*P!0.05 vs control by Student’s t-test. (B) Reversible body weight recovery after withdrawal of CKD-732 treatment in ARC lesion mice
(nZ5 per each subgroup). T0–T6 indicates treatment days and P0–P11 indicates post-treatment days. (C) and (D) Cumulative body
weight difference and food intake of LETO (nZ20) and OLETF rats (nZ20) when 10 mg/kg dose of CKD-732 was s.c. injected for 7 days.
†P!0.001 by one-way ANOVA.
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at a single dose of 0.5, 1, 1.5, 3, or 5 mg/2 ml aCSF using
the stereotaxic technique in ARC lesion mice and
normal littermates. The validity of a single i.c.v.
injection by the stereotaxic technique was proven by
examining the stained ventricle areas with Toluidine
blue, shortly after i.c.v. injection. Body weight, food
intake, and core temperature was measured 4 and 24 h
after CKD-732 i.c.v. injection. Although anorexic effects
were not found in normal littermates, the 24 h body
weight and 4 and 24 h food intakes were significantly
decreased in a dose-dependent manner in ARC lesion
mice (Table 1). However, the core temperature was not
altered in ARC lesion mice and normal littermates by a
single central injection of CKD-732 (Table 1).
To establish the central action of CKD-732 in different
obesity models, 2 mg/2 ml CKD-732 were i.c.v. injected in
five ob/obmice and 2 ml aCSFwas i.c.v. injected in another
five ob/obmiceas controls.Thebasal bodyweights of ob/ob
mice were not significantly different: 36.2G0..72 g vsJournal of Molecular Endocrinology (2007) 38, 455–46536.4G0.55 g (CKD-732 group versus control group;
PZ0.88 by Student’s t-test). Like the results in Table 1, 4
and24 h food intakes were significantly lower in theCKD-
732 group: 0.62G0.19 g vs 1.35G0.15 g and4.30G0.39 g
vs 5.84G0.37 g (CKD-732 group versus control group;
P!0.05 by Student’s t-test respectively). The change in
body weight during 24 h after single i.c.v. injection was
significantly different: K0.38G0.34 g vs 0.96G0.19 g
(CKD-732 group versus control group; P!0.05 by
Student’s t-test).
To verify the changes in hypothalamic neuropeptide
mRNAs when CKD-732 was centrally injected, we killed
ARC lesion mice and normal littermates 1 h after i.c.v.
injection. The basal POMC and NPY mRNA expression
levels in ARC lesion mice were decreased to 41 and 39%
of normal littermates respectively. However, all POMC,
NPY, AgRP, and MCH mRNA expressions were not
significantly altered by CKD-732 i.c.v. injection in ARC
lesion mice and normal littermates beyond our
expectation (Fig. 6).www.endocrinology-journals.org
Figure 4 Reduction of regional fat contents after 7 days of
CKD-732 s.c. injection. Regional fat contents of (A) LETO (nZ10
per subgroup) and (B) OLETF (nZ10 per subgroup) rats are
shown. *P!0.05 vs control by Student’s t-test.
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food intake control, we checked for CTA by a single
peripheral injection of CKD-732. LETO and OLETF rats
with saline injection exhibited no preference for
saccharin flavor. In contrast, the rats in both the LiCl
and CKD-732-treated groups significantly preferred the -
neutral flavor, indicating the development of CTA. In
OLETF rats, the preference ratio was 85.4% for control,
7.9% for LiCl treated, 12.1% for CKD-732 1 mg/kg
treated, and 7.2% for 10 mg/kg treated rats (P!0.01 for
LiCl, 1 mg/kg treated, and 10 mg/kg treated vs control).
Additionally, a CTA produced by administration of CKD-
732 was found to be dose-dependent and more easily
achieved inOLETF thanLETOrats (Fig. 7). These results
suggest that CKD-732 acutely causes CTA, which may
contribute to decreased food intake caused by CKD-732,
especially in obese models.Discussion
To overcome the limitations of obesity therapy, an
angiogenesis inhibitor has recently been speculated as a
potential anti-obesity drug (Rupnick et al. 2002). Like-
wise, Brakenhielm et al. (2004a) have recently proved thewww.endocrinology-journals.orgpreventive effect of the angiogenesis inhibitor, TNP-470,
diet-induced obese models. They showed that TNP-470
decreased serum levels of low-density lipoprotein choles-
terol and insulin levels, and increased insulin sensitivity
(Brakenhielm et al. 2004a). According to their results,
TNP-470 could be useful in preventing obesity and
ameliorating insulin resistance, which is amajor causative
factor for type 2 diabetes mellitus (Elmquist & Marcus
2003). However, the mechanism of such novel drugs on
body weight and food intake control, or metabolic
adaptation, is largely unknown. In order to verify the
anti-obesity action mechanism of the TNP-470 analog,
CKD-732, we evaluated: 1) changes in body weight, food
intake, and core temperature 1 h after a single i.c.v.
injection, 2) alteration of hypothalamic anorexic and
orexigenic neuropeptide expression 1 h after a single
i.c.v. injection, and 3) induction of a CTA by a single s.c.
injection.
In this study, we demonstrated that CKD-732 signi-
ficantly reduced thebodyweight and food intake inobese
and non-obese animal models by peripheral injection.
Previous studies have shown that various angiogenesis
inhibitors haveperipheral anti-obesity effects andprevent
obesity with decreased insulin resistance mainly in obese
animals, as non-obese models were not affected by these
agents (Rupnick et al. 2002, Brakenhielm et al. 2004a).
Apart from previous reports, our findings included
different types of obesity models such as ARC lesion
mouse, whose ARC nucleus was ablated by neonatal MSG
injection, and OLETF rat, which is a model for type 2
diabetes mellitus and obesity. Moreover, we suggest a
modest but similar pattern of CKD-732’s anti-obesity
effects in non-obese models. In terms of animal models,
ARC lesion mice are known to represent hypophagic,
hypometabolic, obese mice, and ob/obmice are known as
leptin-deficient, hyperphagic obese mice, whereas
OLETF rats become obese and develop diabetes mellitus
due to hyperphagia. We experienced similar anti-obesity
effects of CKD-732 in these specific obese models, in that
CKD-732 is effective in both hypometabolic and hyper-
phagic obesity. These effects were induced within
relatively short periods such as 7 days after s.c. CKD-732
injection. After death, the regional fat contents of
epididymal and mesenteric fat pads were significantly
decreased in CKD-732-treated OLETF and LETO rats.
Whenwe evaluated the histopathology of these shrunken
fat pads, we found that the absolute adipocyte number in
each HPF was higher, and thus adipocyte size was
significantly decreased inCKD-732-treated rats. Although
we could not define endothelial cells in the fat pads, the
decreaseof the sizeof adipocytes couldbesurmisedby the
selective apoptosis of endothelial cells in adipose tissue
and shrinkage of existing adipocytes, as presented
previously (Lucas et al. 1998, Dhanabal et al. 1999,
Rupnick et al. 2002, Brakenhielm et al. 2004b). Through
these results, we strongly suggest that CKD-732’s directJournal of Molecular Endocrinology (2007) 38, 455–465
Figure 5 Histopathology of epididymal fat in OLETF and LETO rats after 7 days of CKD-732 s.c. injection. (5-1) H–E stain of epididymal fat
is shown (!200). (A) LETO control, (B) LETO CKD-732 treated, (C) OLETF control, (D) OLETF CKD-732 treated. (5-2) CKD-732
increased the number (n) of adipocytes per HPF and decreased the adipocyte size (m2) significantly. *P!0.05; †P!0.01 vs control by
Student’s t-test.
Y M KIM and others . Anti-obesity effects of CKD-732462stimulation of adipose tissue contributes to one part of an
anti-obesity mechanism causing significant shrinkage of
adipose tissue and subsequent body weight reduction.
Although TNP-470 is a selective angiogenesis
inhibitor, in clinical trials for the treatment of cancer,Table 1 Change of body weight, food intake, and core temperature 4
C57BL/6J mouse (nZ5 per each subgroup)
aCSF 1.0mg 3.0mg 5
24 h BW change (g) 0.36G0.07 0.26G0.22 0.22G0.23 0.25
4 h food intake (g) 1.03G0.02 1.22G0.03 0.99G0.18 1.11
24 h food intake (g) 3.97G0.11 4.13G0.01 4.17G0.33 4.02
Core temperature (8C) 37.37G0.11 37.50G0.18 37.38G0.10 37.54
*P!0.05; †P!0.01 vs control (aCSF i.c.v. injected mice of the same group) by
Journal of Molecular Endocrinology (2007) 38, 455–465high dosages of this agent may affect other systems in
the body. Thus, we cannot exclude the possibility that
CKD-732 may modify obesity through mechanisms
other than antiangiogenesis. For example, CKD-732
affects food intake, even though this reduction seems toand 24 h after CKD-732 intracerebroventricular (i.c.v.) injection
ARC lesion mouse (nZ5 per each subgroup)
.0mg aCSF 0.5mg 1.0mg 1.5mg
G0.07 K0.57G0.08 K0.72G0.05 K0.87G0.16 K1.05G0.15*
G0.14 0.64G0.01 0.57G0.03 0.43G0.02† 0.25G0.06†
G0.33 2.09G0.18 2.34G0.11 1.84G0.16 1.30G0.25*
G0.09 37.44G0.09 37.55G0.08 37.84G0.04 37.82G0.04
one-way ANOVA.
www.endocrinology-journals.org
Figure 6 RT-PCR of hypothalamic neuropeptide mRNA 1 h after single i.c.v. injection of CKD-732. C57BL/6J mice (nZ5 per subgroup),
(A) control and (B) CKD-732 treated. ARC lesion mice (nZ5 per subgroup), (C) control and (D) CKD-732 treated. No significant
neuropeptide mRNA mobilization was observed.
Anti-obesity effects of CKD-732 . Y M KIM and others 463mostly affect obese models, with a modest effect in non-
obese models. In this regard, although the body weight
and food intake of normal littermates were not altered
despite increment of the drug concentration, the bodywww.endocrinology-journals.orgweight and food intake of ARC lesion mice and ob/ob
mice were decreased with a relatively lower dosage than
that of normal littermates. Several reasons may explain
why this central effect was only presented in obese mice,Journal of Molecular Endocrinology (2007) 38, 455–465
Figure 7 Conditioned taste aversion induced by CKD-732 single
s.c. injection. (A) LETO (nZ10 per subgroup) and (B) OLETF rats
(nZ10 per subgroup). CKD-732-treated OLETF and LETO rats
favored neutral flavor, which was more profoundly demonstrated
in OLETF rats. *P!0.05; †P!0.01 vs control by one-way ANOVA
followed by Tukey’s post hoc analysis.
Y M KIM and others . Anti-obesity effects of CKD-732464one of which might be the higher permeability of the
blood–brain barrier in obese models (including ARC
lesion mice and ob/ob mice) when compared with
normal models (Skultetyova et al. 1998). Several
experiments have suggested that blood–brain barriers
of obese models, such as ARC lesion mice and ob/ob
mice, are more permeable than normal animals,
especially under stress conditions (Sharma & Dey
1988, Skultetyova et al. 1998, Peruzzo et al. 2000).
A second explanation for this consequence might be
the different effective dosages needed for different
species or models, as food intake is regulated according
to body size and drug sensitivity. Accordingly, we
propose that an indirect central action of CKD-732
partly account for reduction of food intake in such
animal models.
In terms of regulating energy homeostasis, food intake
and energy balance is influenced by well-known hypo-
thalamic orexigenic or anorexigenic neuropeptides
(Woods et al. 1998). We demonstrated that a single i.c.v.
injection of CKD-732 induced no significant increase or
decrease in various neuropeptides in ARC lesionmice orJournal of Molecular Endocrinology (2007) 38, 455–465in normal littermates. As previously shown, the basal
mRNA expression of NPY and POMC in ARC lesionmice
was decreased to about 40%of that of normal littermates,
which indicates that the selective ablation of the ARC
nucleus may result in a significant decrease of both
orexigenic and anorexigenic signals (Broberger et al.
1998). However, taken together, these data indicate that
the action point of CKD-732 in the hypothalamus does
not affect the transcriptional level of neuropeptides.
Additional experiments that evaluate CKD-732’s
unknown supplementary central mechanism, such as its
regulation of translational or post-translational modifi-
cation of hypothalamic neuropeptides, and that of
secretion or stability of various neuropeptides need to
be performed in the near future.
In developing novel drugs for obesity, some agents
induce unexpected phenomena, which may limit the
use of such agents. Recently, MC studies have shown
that CTA, which is the induction of an abnormal taste or
visceral illness such as nausea or gastrointestinal
discomfort, consequently may decrease food intake
(Abe et al. 1994, Benoit et al. 2003). Moreover, it has
been shown that the reduction of food intake caused by
MTII was accompanied by adverse consequences such
as a mild CTA, regardless of administration route.
Likewise, we experienced a similar CTA by peripheral
injection of CKD-732 in OLETF and LETO rats that was
as significant as LiCl injection. These effects were shown
to be dose-dependent and more profoundly affected
OLETF rats. This result suggests that anorexia caused
by peripheral injection can be partly explained by the
induction of a CTA. However, avoidance of a specific
taste induced by CTA does not represent a direct
decrease in appetite. Besides, the influence of CKD-732
on food intake can only partially explain its anti-obesity
effect because pair-fed control animals were signi-
ficantly more obese than the TNP-470-treated obese
models, as previously shown (Rupnick et al. 2002).
Therefore, we suggest that the TNP-470 analog, CKD-
732, has a multifunctional action that induces direct
shrinkage of adipose tissue and anorexia caused by
direct hypothalamic stimuli or a CTA.
This study has some limitations that should be
addressed in further studies. First, CKD-732 was the
only type of angiogenesis inhibitor we used to evaluate
the anti-obesity effect in our study. Secondly, we
included specific models of obesity, such as ARC lesion
mice, ob/ob mice, and OLETF rats, which may limit the
wide application of such results. Finally, we only used
mouse models when performing i.c.v. injection and
performed a single central stereotaxic injection instead
of a continuous central infusion using cannula with an
osmotic pump when searching for precise regulation of
hypothalamic neuropeptides.
In conclusion, our findings provide some insight into
the mechanism of action of the angiogenesis inhibitor,www.endocrinology-journals.org
Anti-obesity effects of CKD-732 . Y M KIM and others 465CKD-732 on obesity control. CKD-732 was found to
decrease food intake, body weight, fat mass, and the size
of adipocytes. Moreover, although it was only proven in
selected animal models, CKD-732 induced central
anorexia and a CTA. The results of this study should
be carefully referred to and verified when developing
CKD-732 for anti-obesity or anti-cancer treatments.Acknowledgements
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